How is the immune effect of "Jingzhi Cikang"? Spike Health invites you to try
Release time:
2022-06-01
News from our newspaper Recently, Jianfeng Health Technology Company has carried out the activity of measuring the efficacy of Jingzhi Cikang products. It has introduced a saliva detector to measure the changes of human immunity level after taking Jingzhi Cikang continuously for one month. It has carried out more in-depth and detailed research on the actual effect of the products and provided scientific research data support for future product promotion and process improvement.
Jingzhi Cikang is a pure Chinese medicine health care product with sharp peak health. Rhodiola rosea, broken ganoderma lucidum spore powder, astragalus, ginseng, acanthopanax senticosus and cinnamon 6 medicinal materials are enriched with various functional components by modern extraction technology. Among them, Rhodiola rosea and Ganoderma lucidum are commonly used tonic herbs, and Astragalus membranaceus and ginseng are representative drugs for tonifying middle qi and vitality. Combining them with the innovative application of modern technology and the compatibility principle of traditional Chinese medicine, they can enhance human immunity with multiple components, multiple channels and multiple targets.
Health food is different from drugs. There are a total of 27 items of health food approved by the state, of which 7 items, including enhancing human immunity, do not require human trial food at the time of declaration, only safety toxicology test and functional animal test are required. Therefore, although the health food has been demonstrated by experts, the actual effect of taking it is lack of scientific experimental data support.
Peak Health has recently carried out an immunity test activity in the Peak Health Hall on the first floor of Peak Building. People with low immunity shown by the test results are given Jingzhi Cikang products for one month. The change data of immunoglobulin content in human saliva during this period are measured to supplement the data support for the product effect. Immunoglobulin content is an important indicator to measure the level of human immunity. Prior to this, Spike Health has conducted pilot tests among employees and their relatives and friends, collecting nearly 100 data. This testing activity will last for one month. It is expected to collect ,1000 actual use cases, which will make the actual effect of Jingzhi Cikang products have both traditional Chinese medicine theoretical basis and modern scientific data, and make preparations for the follow-up product improvement, publicity and marketing activities of peak health.
(Reporter Chen Shengmu)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page